Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults
AIM: To evaluate the effects of three potentially anti-inflammatory probiotic bacteria from three different genera on immune variables in setting based on previous in cytokine responses. healthy adults in a clinical vitro characterization of METHODS: A total of 62 volunteers participated in this ran...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 14; no. 13; pp. 2029 - 2036 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
University of Helsinki, Institute of Biomedicine, Pharmacology, PO Box 63, 00014 Helsinki, Finland and Valio Ltd, Research Centre, Meijeritie 4, Helsinki 00370, Finland%Valio Ltd, Research Centre, Meijeritie 4, Helsinki 00370, Finland%National Public Health Institute, Department of Viral Diseases and Immunology, Mannerheimintie 166,Helsinki 00300, Finland%Medcare Foundation, Aanekoski, Finland%University of Helsinki, Institute of Biomedicine, Pharmacology, PO Box 63, Helsinki 00014, Finland
07.04.2008
The WJG Press and Baishideng |
Subjects | |
Online Access | Get full text |
ISSN | 1007-9327 2219-2840 |
DOI | 10.3748/wjg.14.2029 |
Cover
Summary: | AIM: To evaluate the effects of three potentially anti-inflammatory probiotic bacteria from three different genera on immune variables in setting based on previous in cytokine responses. healthy adults in a clinical vitro characterization of METHODS: A total of 62 volunteers participated in this randomized, double-blind and placebo-controlled parallel group intervention study. The volunteers were randomized to receive a milk-based drink containing either Lactobacillus rhamnosus GG (LGG), Bifidobacterium animalis ssp. lactis Bb12 (Bb12), or Propionibacterium freudenreichii ssp. shermanii JS (PJS) or a placebo drink for 3 wk. Venous blood and saliva samples were taken at baseline and on d 1, 7 and 21. Fecal samples were collected at baseline and at the end of intervention. RESULTS: The serum hsCRP expressed as the median AUC0-21 (minus baseline) was 0.018 mg/L in the placebo group, -0.240 mg/L in the LGG group, 0.090 mg/L in the Bb12 group and -0.085 mg/L in the PJS group (P = 0.014). In vitro production of TNF-α from in vitro cultured peripheral blood mononuclear cells (PBMC) was significantly lower in subjects receiving LGG vs placebo. IL-2 production from PBMC in the Bb12 group was significantly lower compared with the other groups. CONCLUSION: In conclusion, probiotic bacteria have strain-specific anti-inflammatory effects in healthy adults. |
---|---|
Bibliography: | Probiotic Immune response Mononuclearcells 14-1219/R Probiotic; Highly sensitive C-reactive protein;Cytokine; Inflammation; Immune response; Mononuclearcells Cytokine Highly sensitive C-reactive protein Inflammation R392 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Author contributions: Kekkonen RA designed and coordinated the study, did the PBMC analysis participated in the interpretation of the results and wrote the paper; Lummela N participated in planning the study, was responsible for the study visits and created the database; Latvala S helped in the PBMC analysis; Karjalainen H and Tynkkynen S were responsible for the microbiological analysis; Kautiainen H and Järvenpää S participated in planning the study, carried out the statistical analysis, participated in the interpretation of the results and revised the manuscript; Julkunen I offered expertise in immunology and revised the manuscript; Vapaatalo H participated in planning the study and in the interpretation of the results, supervised the study and revised the manuscript; Korpela R initiated the study, participated in planning the study and the interpretation of the results, was responsible for the management of the study, and revised the manuscript. Telephone: +35-810-3813026 Fax: +35-810-3813019 Correspondence to: Riitta Korpela, PhD, Assistant Professor, Institute of Biomedicine, Pharmacology, PO Box 63, 00014 Univ-ersity of Helsinki, Helsinki 00014, Finland. riitta.korpela@valio.fi |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.14.2029 |